These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33252854)

  • 21. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
    Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
    Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities.
    Molnár I; Szentmiklósi JA; Somogyiné-Vári É
    Exp Clin Endocrinol Diabetes; 2017 Sep; 125(8):514-521. PubMed ID: 28750432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
    Mourits MP; Prummel MF; Wiersinga WM; Koornneef L
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):9-14. PubMed ID: 9302365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic factors in Graves' ophthalmopathy.
    Frecker M; Stenszky V; Balazs C; Kozma L; Kraszits E; Farid NR
    Clin Endocrinol (Oxf); 1986 Nov; 25(5):479-85. PubMed ID: 3113776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic indicators for the development of strabismus among patients with graves' ophthalmopathy.
    Lin TY; Li N; Yeh MW; Leung AM; Rootman DB
    J Clin Transl Endocrinol; 2017 Sep; 9():38-40. PubMed ID: 29067268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.
    Nishikawa M; Yoshimura M; Toyoda N; Masaki H; Yonemoto T; Gondou A; Kato T; Kurokawa H; Furumura T; Inada M
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):213-9. PubMed ID: 8105634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
    Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin.
    Tellez M; Cooper J; Edmonds C
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):291-4. PubMed ID: 1563082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latanoprost is effective in reducing high intraocular pressure associated with Graves' ophthalmopathy.
    Gumińska M; Kłysik A; Siejka A; Jurowski P
    Klin Oczna; 2014; 116(2):89-93. PubMed ID: 25345284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features of Graves' ophthalmopathy in an incidence cohort.
    Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
    Am J Ophthalmol; 1996 Mar; 121(3):284-90. PubMed ID: 8597271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients.
    Esteghamati A; Khalilzadeh O; Mobarra Z; Anvari M; Tahvildari M; Amiri HM; Rashidi A; Solgi G; Parivar K; Nikbin B; Amirzargar A
    Eur J Intern Med; 2009 Jul; 20(4):424-8. PubMed ID: 19524188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detectable serum IgE levels in Graves' ophthalmopathy.
    Molnár I; Horváth S; Balázs C
    Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
    Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
    N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
    Ohtsuka K; Hashimoto M
    Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graves' ophthalmopathy. A clinical and immunologic review.
    Sergott RC; Glaser JS
    Surv Ophthalmol; 1981; 26(1):1-21. PubMed ID: 6895125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.